Adverse Drug Reaction Classification System

         

ADR Ontology
ADR Term Bladder transitional cell carcinoma
ADR ID BADD_A06952
ADR Hierarchy
16      Neoplasms benign, malignant and unspecified (incl cysts and polyps)
16.08      Renal and urinary tract neoplasms malignant and unspecified
16.08.01      Bladder neoplasms malignant
16.08.01.002      Bladder transitional cell carcinoma
20      Renal and urinary disorders
20.03      Bladder and bladder neck disorders (excl calculi)
20.03.04      Bladder neoplasms
20.03.04.003      Bladder transitional cell carcinoma
Description Not Available
MedDRA Code 10005084
MeSH ID Not Available
ADR Severity Grade (FAERS)
ADR Severity Grade (CTCAE) Not Available
Synonym
Adenocarcinoma with transitional cell carcinoma of bladder NOS | Bladder transitional cell carcinoma | Squamous cell with transitional cell carcinoma of bladder NOS | Transitional cell carcinoma of the bladder stage unspecified | Urothelial carcinoma bladder | Adenocarcinoma with transitional cell carcinoma of bladder | Squamous cell with transitional cell carcinoma of bladder | Papillary transitional cell carcinoma of bladder | Non-invasive papillary transitional cell carcinoma of bladder | Non-invasive papillary urothelial carcinoma of bladder | Non-muscle invasive bladder cancer | NMIBC
Drugs Leading to the ADR
Drug IDDrug NameADR Frequency (FAERS)ADR Severity Grade (FAERS)
BADD_D00347Candesartan cilexetil0.000841%
BADD_D00589Dasatinib0.000112%
BADD_D00680Dimethyl fumarate0.000600%
BADD_D00765Empagliflozin0.000137%
BADD_D01136Imatinib0.000336%
BADD_D01260Leuprolide acetate0.001434%
BADD_D01300Lisinopril0.000007%
BADD_D01401Metformin0.000008%
BADD_D01777Pioglitazone0.006223%
BADD_D01831Prednisolone0.000035%
BADD_D01913Ranitidine0.000063%
BADD_D02111Tamoxifen0.000238%
BADD_D02272Triamcinolone acetonide--
The 1th Page    1    Total 1 Pages
ADReCS-Target
ADR Term Drug Name Target